Keywords: Progenics, Wyeth, Relistor, Licensing, Opioid induced constipation
Progenics regains global rights to Relistor from Wyeth; will seek new partners
Article | 15 October 2009
USA-based Progenics Pharmaceuticals says it is regaining all worldwide rights to the Relistor (methylnaltrexone) franchise from drug major Wyeth (which is in the process of being acquired by Pfizer in a $68 billion deal). Progenics licensed the drug to Wyeth Pharmaceuticals in 2005.
Progenics said it will assume full control of future development and commercialisation of subcutaneous Relistor after a one-year transition, and will immediately take over development of the oral form of the drug, as well as looking for a new partner .Relistor generated $3.2 million in sales in the second quarter of 2009, and analysts from Cowen & Co forecast annual revenue for the drug could reach $90 million by 2012. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
